Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray

NCT06461949 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Closed by sponsor, lack of enrollment.

Conditions

Allergic Fungal Rhinosinusitis (AFRS)
Chronic Rhinosinusitis (CRS)
Asthma
Nasal Polyps

Interventions

DRUG: Dupilumab

Sponsor

National Institute on Deafness and Other Communication Disorders (NIDCD)